Instrument Business Outlook Names Bio-Techne 2016 Company of the Year
LOS ANGELES, Jan. 23, 2017 /PRNewswire/ -- Instrument Business Outlook (IBO) today named Bio-Techne (Minneapolis, MN) the 2016 Company of the Year. IBO is the most authoritative newsletter tracking developments in the analytical and life science instrumentation and consumables market.
"Bio-Techne consistently achieved outstanding technical, operational and financial results throughout the year," said Tanya Samazan, Managing Editor of IBO. "In 2016, Bio-Techne capitalized on opportunities in life science research and biopharma drug development to drive top line growth, expand geographically, and solidify both its core consumables product line and its newer instrument and diagnostic pathology businesses."
IBO monitors market developments at hundreds of life science and analytical instrument companies on a daily basis. "Beginning in early January, we compared and contrasted the overall performance of the market's leaders and it was soon clear that Bio-Techne was outpacing its peers with sales growing more than 60% over the last three years," explained Samazan. "The company has executed a smart acquisition strategy acquisitions, introduced successful new products, and expanded globally."
IBO's annual Company of the Year award is featured in the publication's 2017 Industry Forecast Issue, now available for purchase. The 39-page Forecast Issue highlights trends and projects expected growth in ten major segments of the life science and analytical instrument and consumables market, as well as an analysis of regional and end-market developments.
ABOUT IBO and BIOINFORMATICS LLC
Instrument Business Outlook (IBO) provides expert insights, commentary and analysis of the news and developments impacting the life science and analytical instrument and consumables market. IBO is a publication of BioInformatics LLC and its SDi division that together forms the premier research and advisory firm serving senior executives at companies making the tools of science. By leveraging our expert network of more than 75,000 scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact:
Tanya Samazan
Managing Editor
Instrument Business Outlook
A publication of BioInformatics LLC
6242 Westchester Parkway, Suite 100
Los Angeles, CA 90045-4820
United States
Phone: 310.641.4982
[email protected]
www.gene2drug.com
SOURCE BioInformatics LLC
Share this article